Pasar al contenido principal

NUEVAS HERRAMIENTAS TERAPEUTICAS FRENTE A INFLUENZA Y TUBERCULOSIS: DISEÑO DE FARMACOS GUIADO POR MULTIVALENCIA, CRIBADO BASADO EN HIDROFOBOBICIDAD Y MODIFICACION COVALENTE

PID2023-147942OB-I00

•
Nombre agencia financiadora Agencia Estatal de Investigación
Acrónimo agencia financiadora AEI
Programa Programa Estatal para Impulsar la Investigación Científico-Técnica y su Transferencia
Subprograma Subprograma Estatal de Generación de Conocimiento
Convocatoria Proyectos de I+D+i (Generación de Conocimiento y Retos Investigación)
Año convocatoria 2023
Plan Estatal 2021-2023 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario UNIVERSIDAD DE BARCELONA

Resultados relacionados

Resultados totales (Incluyendo duplicados): 2
Encontrada(s) 1 página(s)

RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publicación Artículo científico (JournalArticle)

Spiranic compounds as novel AMPK paradoxical inhibitors: can we derive new mechanistic

  • Sanz-Gomez, Marta
  • Barmpidi, Katerina
  • Quesada-Sanchez, Sergio
  • Cumella, Jose
  • Perez, Concepcion
  • Sanz, Pascual
  • Doyaguez, Elisa G.
  • Infantes, Lourdes
  • Luque, Francisco Javier
  • Castro, Ana
  • Lagartera, Laura
  • Fernandez-Alfonso, Maria S.
  • Estarellas, Carolina
  • García-Gimeno, María Adelaida|||0000-0002-6483-3912
[EN] In this study, we synthesized and fully characterized spiranic compounds designed as conformationally restricted mimetics of A-769662 by means of crystallographic, spectroscopic, and computational methods. In vitro enzymatic assays and surface plasmon resonance experiments revealed a mixed-type inhibition mechanism. We developed a stable and equilibrated alpha 1(31 AMPK model featuring the A-loop in a closed conformation, which was used to investigate alternative binding pockets beyond the canonical AMPK sites, namely type II-like pocket. The cell-based and tissue experiments further demonstrated that these compounds act as paradoxical inhibitors, since it enhances downstream signalling by increasing phosphorylation of ACC and eNOS, ultimately activating the AMPK-eNOS-NO pathway and inducing vasodilation in rat aorta. Altogether, our findings offer new insights into AMPK modulation and highlight the potential of spiranic scaffolds as tools for probing alternative regulatory mechanisms., This research was supported by Fundacion Eugenio Rodriguez Pascual, the Spanish Ministerio de Economia y Competitividad [CEX2021-001202-M] , the Spanish Ministerio de Ciencia Innovacion y Universidades [PID2023-147942OB-I00, PID2022-142623OA-I00, PID2020-117400 GB-100] and the Generalitat de Catalunya [2021SGR00671] . Computational resources from the Barcelona Super-computing Center (BSC; BCV-2022-1-0014 and BCV-2023-2-0020) and the Consorci de Serveis Universitaris de Catalunya (CSUC; Molecular Recognition project) are acknowledged. M.S.G. thanks Universidad Complutense de Madrid for her fellowship. K.B. thanks Generalitat de Cataluna for FI fellowship [2023 FISDU 00519] .
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Spiranic compounds as novel AMPK paradoxical inhibitors: can we derive new mechanistic insights?

  • Sanz-Gómez, Marta
  • Barmpidi, Katerina
  • Quesada-Sánchez, Sergio
  • Cumella, José
  • Pérez, Concepción
  • García-Gimeno, María Adelaida
  • Sanz, Pascual
  • Doyagüez, Elisa G.
  • Infantes, Lourdes
  • Luque, Francisco Javier
  • Castro Morera, Ana
  • Lagartera, Laura
  • Fernández-Alfonso, María S.
  • Estarellas, Carolina
In this study, we synthesized and fully characterized spiranic compounds designed as conformationally restricted mimetics of A-769662 by means of crystallographic, spectroscopic, and computational methods. In vitro enzymatic assays and surface plasmon resonance experiments revealed a mixed-type inhibition mechanism. We developed a stable and equilibrated α1β1 AMPK model featuring the A-loop in a closed conformation, which was used to investigate alternative binding pockets beyond the canonical AMPK sites, namely type II-like pocket. The cell-based and tissue experiments further demonstrated that these compounds act as paradoxical inhibitors, since it enhances downstream signalling by increasing phosphorylation of ACC and eNOS, ultimately activating the AMPK-eNOS-NO pathway and inducing vasodilation in rat aorta. Altogether, our findings offer new insights into AMPK modulation and highlight the potential of spiranic scaffolds as tools for probing alternative regulatory mechanisms., This research was supported by Fundación Eugenio Rodríguez Pascual, the Spanish Ministerio de Economía y Competitividad [CEX2021-001202-M], the Spanish Ministerio de Ciencia Innovación y Universidades [PID2023-147942OB-I00, PID2022-142623OA-I00, PID2020-117400GB-100] and the Generalitat de Catalunya [2021SGR00671]. Computational resources from the Barcelona Supercomputing Center (BSC; BCV-2022-1-0014 and BCV-2023-2-0020) and the Consorci de Serveis Universitaris de Catalunya (CSUC; Molecular Recognition project) are acknowledged. M.S.G. thanks Universidad Complutense de Madrid for her fellowship. K.B. thanks Generalitat de Cataluña for FI fellowship [2023 FISDU 00519]., Peer reviewed